Capricor Therapeutics (NASDAQ:CAPR) Stock Rating Reaffirmed by HC Wainwright

HC Wainwright reissued their buy rating on shares of Capricor Therapeutics (NASDAQ:CAPR) in a report issued on Thursday morning, Benzinga reports. The brokerage currently has a $40.00 target price on the biotechnology company’s stock.

A number of other equities research analysts also recently weighed in on CAPR. Cantor Fitzgerald assumed coverage on shares of Capricor Therapeutics in a research note on Friday, January 5th. They set an overweight rating and a $8.00 price target on the stock. StockNews.com upgraded shares of Capricor Therapeutics from a sell rating to a hold rating in a research note on Wednesday, January 24th.

Capricor Therapeutics Stock Performance

NASDAQ CAPR opened at $5.41 on Thursday. Capricor Therapeutics has a twelve month low of $2.68 and a twelve month high of $8.22. The stock has a market cap of $170.43 million, a PE ratio of -6.22 and a beta of 3.99. The firm has a 50-day simple moving average of $5.65 and a 200 day simple moving average of $4.39.

Capricor Therapeutics (NASDAQ:CAPR) last posted its quarterly earnings results on Thursday, February 29th. The biotechnology company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.21. Capricor Therapeutics had a negative return on equity of 299.67% and a negative net margin of 88.52%. The firm had revenue of $12.09 million during the quarter, compared to analysts’ expectations of $5.80 million. Research analysts forecast that Capricor Therapeutics will post -0.83 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Capricor Therapeutics

A hedge fund recently bought a new stake in Capricor Therapeutics stock. Citigroup Inc. purchased a new stake in shares of Capricor Therapeutics Inc (NASDAQ:CAPR) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 61,591 shares of the biotechnology company’s stock, valued at approximately $211,000. Citigroup Inc. owned approximately 0.20% of Capricor Therapeutics at the end of the most recent reporting period. Institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.